Myalgic encephalomyelitis (ME, also known as ME/CFS) and long COVID are highly complex chronic conditions.
PrecisionLife has undertaken multiple landmark studies in ME and long COVID and identified the first reproducible disease mechanisms and clinically actionable patient subgroups for both conditions.
These studies include the most detailed genetic analysis of ME ever performed, identifying over 250 core genes associated with the disease, revealing clear areas of biological overlap with long COVID, and discovering multiple drug repurposing opportunities with biomarker tests to find the patients who would most likely benefit from them.
With this new understanding, we're driving better diagnosis, treatment, and prevention of these debilitating diseases.
Learn about this foundational research:
|
|
Read the interim report of the progress made in understanding ME/CFS and long COVID and finding new diagnostic and therapeutic options. 
|
-min.png?width=990&height=518&name=LOCOME%20(Landscape)-min.png)
Further studies |
|
|
Reproducibility of Genetic Risk Factors Identified for Long COVID using Combinatorial Analysis Across US and UK Patient Cohorts with Diverse Ancestries |
Genetic Risk Factors for ME/CFS, Long COVID & their Similarities |
 |
 |
|
|
|
|
|
Genetic Risk Factors for Severe and Fatigue Dominant Long COVID and Commonalities with ME/CFS Identified by Combinatorial Analysis |
 |
 |
|
|
 |
|
|
|
How new research confirmed long COVID genetic associations for diagnostics and treatments |
New Study Links 14 Genes to ME/CFS |
 |
 |
Partners
.png?width=1000&height=180&name=MECFS%20long%20COVID%20partners%20(1).png)
Datasets
